

Improving Care Coordination for Patients on Oral Oncolytic Therapy

Hematology-Oncology Associates of Central New York

June 18, 2021



Hematology-Oncology Associates of CNY





The **Mission** of HOA is to provide the highest level of quality care in a healing environment for the mind, body and spirit of patients dealing with cancer and blood disorders. Our goal is to offer the highest level, state of the art technology and treatments, while meeting the emotional needs of our patients and their families.

About HOA

14 Medical Oncologists • 4 Radiation Oncologists
 I Thoracic Surgeon • I Palliative Care Physician
 33 Advanced Practice Providers

HOA by the numbers...

- ~ 19,000 unique patients / year (60% oncology)
- ~ 5,000 new consults / year
- ~ 42% Medicare FFS 18% Medicare Advantage 38% Commercial



Team HOA

Team Lead Anthony Scalzo, MD, MEDICAL ONCOLOGIST, PAST PRESIDENT

Project Sponsor Jennifer Pichoske, MS, FNP-C, AOCNP, CHIEF CLINICAL OFFICER

Team Members

Olivia Barrett, MA, RN, OCN, CPHQ, HEALTHCARE BUSINESS ANALYST

Robin Burke, PATIENT NAVIGATOR MANAGER Jonas Congelli, RPh, CHIEF OF PHARMACY, LABORATORY & NUTRITION SERVICES

Melissa McCormick, BSN, RN, OCN, CLINICAL NURSE MANAGER

Stacy Keppler, Pharm D, BCPS, MANAGER OF DISPENSING PHARMACY SERVICES Matthew Korzeniewski, RN, DIRECTOR OF HEALTH INFORMATION & PATIENT SERVICES Cherie Sgarlata, MSN, NP-C, AOCNP, NURSE PRACTITIONER, MEDICAL ONCOLOGY

ASCO COACHES Vedner Guerrier, MBA, LSSBB John Bingham, MHA





Problem Statement

MISALIGNMENT OF IBRANCE DISPENSE & OFFICE VISITS

55% of Ibrance dispenses from The Patient Rx Center (TPRxC) occur outside of our specified timeframe; either more than 3-days after their office visit, or the dispense occurred before the office visit. *This results in inefficient care and wastes resources, impacting patient satisfaction and leading to both patient & staff frustration.*




Outcome Measure: Baseline Data Summary

Item	Description	
Measure	The proportion of patients that received Ibrance within 3-days after their office visit	
Patient population	Patients with metastatic breast cancer that had a script for Ibrance, filled at our in house dispensing pharmacy, between July 1, 2020 – December 31, 2020	
Calculation methodology	Difference between office visit date & Ibrance dispense date	
Data source	OncoEMR documentation	
Data collection frequency	One time data collection for the baseline period	
Data limitations	Inconsistencies in documentation, manual data abstraction	



Summary of Baseline Data






Aim Statement




ALIGNMENT OF IBRANCE DISPENSE & OFFICE VISITS We aim to increase the percentage of *coordinated office visits* & *Ibrance dispenses* (within the defined 3-day window) from **45%** (during the baseline period of July 2020


-December 2020) to 80% between May 1st - May 31st, 2021.








Cause & Effect Analysis





Priority / Pay-off Matrix





Test of Change: PDSA Plan

ACT STUDY	Date	PDSA Description	Result
Patient Navigator Team	4/19/2021 – 5/31/2021	 Schedule "medication pick-up" appointments with each cycle TPRxC "stop sign" & queueing 	Decreased number of patients missing their medication pick-up. Increased awareness amongst navigator team.
TPRxC Team	4/19/2021 – 5/31/2021	 New activity to document TPRxC dispense Second check / 'tasking' APP in the EMR if cycle dates are not aligned, etc. 	Enhanced accuracy & visibility of the treatment plan; improved communication.
APP Team	4/19/2021 – 5/31/2021	 Enhanced weekly APP-Nurse Navigator communication specifically to review patients on oral therapy Addition of the medication pick-up order Verification of the care plan & future orders 	Improved communication across team; proactive identification of patient needs and coordination of future appointments.
Nursing Team	4/19/2021 – 5/31/2021	 Weekly APP-Nurse Navigator huddle 10-day ONN follow-up, then individualized care plan/follow-up 	Improved communication & standardized Nurse Navigation / patient outreach.

ASCO® Quality Training Program

PLAN

DO




Enhanced Care Plan Accuracy & Visibility

		1				1		
<=More (150) M	ore=> (14)	Tue 05/04/2021 ∢		Fri 05/07/2021	Mon 05/10/2021	Tue 06/01/2021	Thu 06/03/2021	Fri 06/04/2021
CBC Auto Diff		*				*		
Chg Hx (Show)								
CMP		*				*		
MD Office						Kumar/99215		
MD Office NP/PA		Zimmermann/9						
Medication Pick up			Picked-up/DD				Picked-up/BJ	
Hide FH_BRC7: Palb	ociclib PO(125			47:1				48:1
Palbociclib (Ibrance)	PO			75 mg				75 mg
CBC Auto Diff								
CMP								
TX Comment				*				*
Oral Chemo Review								
Charge Nurse Infusio	on Review							
TPRxC Dispense			Picked Up/MM				Picked Up/BJ	
Hide Bone Met: Xgev	a every 1 mon		52:1				53:1	
Denosumab (Xgeva)	SQ		120 mg				120 mg	
			-					



Outcome Measure: Change Data



Outcome Measures: Change Data

MEASURE	Pre-Intervention (7/1/2020 - 12/31/2020)	Post-Intervention (5/1/2021 - 5/31/2021)
Dispense occurs same day or within 3-days after office visit	45%	74%
Dispense occurs sume day of within 5 days after office visit	(124/273)	(28/38)
Dispense occurs same day or within 3-days after labs	78%	87%
Dispense occurs same day of within 5-days after labs	(212/273)	(33/38)
Dispense occurs same day or within 3-days prior to start of next cycle	72%	82%
Dispense occurs same day of within 5-days prior to start of next cycle	(77/107)	(31/38)



Sustainability Plan

Next Steps	Owner
COMMUNICATION : Continue interdisciplinary project meetings. - Team progress reports & check-ins regarding project-specific interventions.	QTP Team
 DATA: Automate data collection, regular data review & communication of results. Create a pharmacy dashboard to monitor patients on oral therapy & pertinent metrics. 	QTP Team



Conclusions & Lessons Learned

- HOA increased the percentage of Ibrance dispenses that met our defined specifications from 45% to 74%
 - > We did not hit our 80% target
 - Achieved improvements in two related metrics

> Wins!

- Positive feedback from staff
- Enhanced communication across teams
- Improved accuracy & visibility of the patient's treatment plan
- Culture of continuous quality improvement
- Data-driven QI project -- keys to success







Improving Care Coordination for Patients on Oral Oncolytic Therapy

AIM To increase the percentage of *coordinated office visits* & *Ibrance dispenses* (within the defined 3-day window) from **45%** (during the baseline period of July 2020 - December 2020) to **80%** between May 1 & May 31st, 2021.


INTERVENTIONS

- Added "medication pick-up" appointment to the patient's schedule, enhancing visibility, compliance & tracking
- Implemented use of a laminated pharmacy "stop sign" to prompt patients to stop at the pharmacy before leaving
- Updated oral care plans to include a pharmacy dispense activity, increasing clarity of the treatment flowsheet
- Enhanced weekly communication between Advanced Practice Provider & Oncology Nurse Navigator (ONN) to review patients on orals, encouraging comprehensive review of patient's needs, treatment plan & future orders
- Standardized the initial ONN follow-up for patients on oral therapy

HOACNY TEAM

Olivia Barrett, MA, RN, OCN, CPHQ Robin Burke Jonas Congelli, RPh Melissa McCormick, BSN, RN, OCN Stacy Keppler, PharmD, BCPS Matthew Korzeniewski, RN Cherie Sgarlata, MSN, NP-C, AOCNP ASCO QTP Coaches Vedner Guerrier, MBA, LSSBB

Vedner Guerrier, MBA, LSSB John Bingham, MHA





THANK YOU



Team HOA

BACK ROW: Missy McCormick ♦ Anthony Scalzo ♦ Matthew Korzeniewski ♦ Robin Burke ♦ Jonas Congelli FRONT ROW: Jennifer Pichoske ♦ Olivia Barrett ♦ Cherie Sgarlata ♦ Stacy Keppler



